BioSpace News Archive

Partnership with Huadong Medicine Accelerates Development and Commercialization of Mirvetuximab Soravtansine in Greater China Encouraging Anti-Tumor Activity and Tolerability Data from FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin ® in Platinum-Sensitive Ovarian Cancer Presented at ESMO FDA Breakthrough Therapy Designation Received for IMGN632 in Relapsed or Refractory BPDCN

Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in upcoming virtual investor conferences and events in November and December. Details of the events are as follows: H.C. Wainwright 6th Annual Israel Conference Presentation on November 12, 2020 at 9:0

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2020. Third Quarter Highlights Net revenues of $83.4 million for the third quarter GAAP net income of $3.9 million, or $0.08 per share, for the third quarter Adjusted non-GAAP net income of $7.6 million, or $0.15 per share, for the third quarter Dr. Jack Zhang, Amphastar’s President an

The dermal allograft market may invite considerable growth during the assessment period of 2020-2030.

The platelet function test market may garner considerable growth during the assessment period of 2020-2030.

The Board of Directors of Moberg Pharma AB has resolved to carry out a fully guaranteed issue of new ordinary shares and warrants with preferential rights for existing shareholders of approximately SEK 150 million before transaction costs.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced that industry veteran Susan Benton was appointed to its board of directors, effective November 5, 2020.

Q3 2020 Net Revenue of $519 million; GAAP Net Loss of $(9) million; Diluted Loss per Share of $(0.06) ‒ ‒ Q3 2020 Adjusted Net Income (1) of $49 million; Adjusted EBITDA (1) of $114 million; Adjusted Diluted EPS (1) of $0.16‒ ‒ Updating 2020 Full Year Financial Outlook ‒

Karen S. Lynch Named the Next President and CEO of CVS Health and Larry J. Merlo to Retire in Spring 2021.

Expansion of Loan Facility with Pharmakon Advisors; $150 Million Drawn Down to Fund Important Growth Initiatives and Extend Operating Runway into At Least 2023